RARA and acute promyelocytic leukemia: A 90-year-old woman was reported as APL with FIP1L1::RARA fusion achieving a complete remission by oral administration of ATRA alone in a dose of 50 mg daily without further follow-up information, indicating a high sensitivity to ATRA (9).